低氧诱导因子脯氨酰羟化酶抑制剂治疗肾性贫血的研究进展

Clinical research progress of hypoxia inducible factor prolyl hydroxylase inhibitor treating renal anemia

低氧诱导因子脯氨酰羟化酶(HIF-PHD)通路被证实负责调节促红细胞生成素(erythropoietin,EPO)生成及维持铁平衡。HIF-PHD抑制剂(HIF-PHIs)是针对HIF-PHD途径研究的药物,有望成为治疗慢性肾脏病(chronic kidney disease,CKD)贫血的替代方法。HIF-PHI是口服的活性小分子,与传统外源性补充EPO的给药途径相比,可通过稳定HIF来刺激内源性EPO生成并改善铁代谢。综述了HIF-PHI的作用机理,临床开发的新进展及未来前景,以期为临床提供参考。

The hypoxia inducible factor prolyl hydroxylase(HIF-PHD)pathway has been confirmed to be responsible for regulating erythropoietin(erythropoietin,EPO)production and maintaining iron balance.HIF-PHD inhibitor(HIF-PHIs)is a drug for HIF-PHD pathway and is expected to be an alternative method for anemia in the chronic kidney disease(CKD).HIF-PHI is an oral active small molecule.Compared with the traditional administration route of exogenous supplement of EPO,HIF-PHI stimulates the production of endogenous EPO and improves iron metabolism by stabilizing HIF.This review summarizes the mechanism of action,new progress in clinical development and future prospects of HIF-PHI,in order to provide reference for clinical practice.